cefiderocol and Pneumonia

cefiderocol has been researched along with Pneumonia* in 5 studies

Other Studies

5 other study(ies) available for cefiderocol and Pneumonia

ArticleYear
Successful treatment of MDR Stenotrophomonas maltophilia-associated pneumonia with cefiderocol-based regimen in a patient with hematological malignancy.
    Annals of hematology, 2022, Volume: 101, Issue:12

    Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Gram-Negative Bacterial Infections; Hematologic Neoplasms; Humans; Pneumonia; Stenotrophomonas maltophilia

2022
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection.
    Antimicrobial agents and chemotherapy, 2021, 02-17, Volume: 65, Issue:3

    Topics: Anti-Bacterial Agents; Bacteremia; Cefiderocol; Cephalosporins; Humans; Microbial Sensitivity Tests; Pneumonia; Sepsis; Siderophores; Urinary Tract Infections

2021
Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration.
    International journal of antimicrobial agents, 2021, Volume: 58, Issue:3

    Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Coinfection; Continuous Renal Replacement Therapy; Critical Illness; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Pneumonia; Stenotrophomonas maltophilia

2021
Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia.
    The Journal of antimicrobial chemotherapy, 2021, 10-11, Volume: 76, Issue:11

    Lung penetration of cefiderocol, a novel siderophore cephalosporin approved for treatment of nosocomial pneumonia, has previously been evaluated in healthy subjects. This study assessed the intrapulmonary pharmacokinetic profile of cefiderocol at steady state in hospitalized, mechanically ventilated pneumonia patients.. Patients received cefiderocol 2 g (or ≤1.5 g if renally impaired), administered IV q8h as a 3 h infusion, or 2 g q6h if patients had augmented renal function (estimated CLCR > 120 mL/min). After multiple doses, each patient underwent a single bronchoalveolar lavage (BAL) procedure either at the end of the infusion or at 2 h after the end of infusion. Plasma samples were collected at 1, 3, 5 and 7 h after the start of infusion. After correcting for BAL dilution, cefiderocol concentrations in epithelial lining fluid (ELF) for each patient and the ELF/unbound plasma concentration ratio (RC, E/P) were calculated. Safety was assessed up to 7 days after the last cefiderocol dose.. Seven patients received cefiderocol. Geometric mean ELF concentration of cefiderocol was 7.63 mg/L at the end of infusion and 10.40 mg/L at 2 h after the end of infusion. RC, E/P was 0.212 at the end of infusion and 0.547 at 2 h after the end of infusion, suggesting delayed lung distribution. There were no adverse drug reactions.. The results suggest that cefiderocol penetrates the ELF in critically ill pneumonia patients with concentrations that are sufficient to treat Gram-negative bacteria with an MIC of ≤4 mg/L.

    Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Humans; Pneumonia; Respiration, Artificial

2021
Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report.
    The Journal of antimicrobial chemotherapy, 2019, 11-01, Volume: 74, Issue:11

    Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Compassionate Use Trials; Critical Illness; Drug Resistance, Multiple, Bacterial; Humans; Influenza, Human; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Pneumonia; Treatment Outcome

2019